Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Nivolumab and Atezolizumab, with related work in Bevacizumab, Quantitative susceptibility mapping, Alveolar soft part sarcoma. Notable publications include 'Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study', 'Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping', and 'Strategies targeting angiogenesis in advanced non-small cell lung cancer'.
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
Current status of PD-(L)1 inhibitor usage in advanced or metastatic non-small cell lung cancer: A national survey of oncologists in China.
Effectiveness and safety of human type 5 recombinant adenovirus (<scp>H101</scp>) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real‐world study
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
Abstract CT218: Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) for Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870
Strategies targeting angiogenesis in advanced non-small cell lung cancer
Crystallin αB acts as a molecular guard in mouse decidualization: Regulation and function during early pregnancy
Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping